All In Biotech

Free tool

FAERS Monitor: Lotensin Hct

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020033 or its brand name (Lotensin Hct, Benazepril Hydrochloride, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.

Reports

447

Serious

265

59% of reports

Hospitalization

145

Death reported

27

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness30
  • diarrhoea24
  • nausea23
  • headache21
  • hypertension21
  • pain19
  • fatigue18
  • blood glucose increased17
  • dyspnoea17
  • pain in extremity16
  • vomiting16
  • arthralgia15
  • drug ineffective15
  • anxiety14
  • asthenia14

Reports by year received

View as table
YearReports
200410
200519
200615
200711
200819
200921
201019
201118
201224
201316
201436
201525
201635
201724
201839
201932
202022
202113
20224
202310
202410
202512
202613

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,712 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypertensionSignal214.73.157
blood glucose increasedSignal174.22.739
dizzinessSignal302.82.035
pain in extremitySignal162.61.614
anxietySignal142.31.49
asthenia141.81.04
diarrhoea241.71.27
arthralgia151.71.04
vomiting161.61.03
headache211.61.04
pain191.50.92
dyspnoea171.40.92
nausea231.40.92
fatigue181.10.70
drug ineffective150.50.36

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.